Nachrichten zur Regeneron Pharmaceuticals Aktie

Regeneron, Sanofi Look for Billions From COPD Drug

The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease....…

Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic…

Regeneron draws more bullish views from analysts after Dupixent COPD data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?

Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Health Care Down as Sanofi, Regeneron Rise -- Health Care Roundup

Health Care Down as Sanofi, Regeneron Rise -- Health Care Roundup...…

Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded…

Why Shares of Regeneron Are Rising Thursday

Regeneron released positive phase 3 trial results for its therapy Dupixent....…

Regeneron up 7% following Dupixent data, Raymond James upgrade

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Coinbase’ stock tumbles on SEC warning, while First Republic and Regeneron shares rally, and other stocks on the move

Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday....…

Regeneron, Sanofi say Dupixent works in COPD

Shares of Regeneron Pharmaceuticals Inc. REGN rallied about 7% in premarket trading on Thursday after the company said a pivotal…

Sanofi erzielt Studienerfolg mit Dupixent bei COPD

Von Adria Calatayud PARIS (Dow Jones)--Sanofi hat einen Studienerfolg mit seinem gemeinsam mit Regeneron Pharmaceuticals entwickelten Medikament Dupixent zur…

Sanofi And Regeneron Say Phase 3 Study Of Dupixent To Treat COPD Meets Endpoints

PARIS (dpa-AFX) - Sanofi S.A. (SNYNF) and Regeneron Pharmaceuticals, Inc. (REGN) on Thursday said late-stage study of their Dupixent for…

Regeneron (REGN) Gets Label Extension for Cholesterol Drug

Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia....…

Regeneron: FDA Approves Evkeeza To Treat Ultra-rare Form Of High Cholesterol In Young Children

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) said that the U.S. Food and Drug Administration has approved Evkeeza (evinacumab-dgnb) to…

Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN

Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN...…

Regeneron (REGN) Gains But Lags Market: What You Should Know

Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session....…

Sanofi, Regeneron Dupixent gets approval in EU to treat eczema in kids over 6 months

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe

...PARIS, March 21 (Reuters) - Healthcare companies Sanofi and Regeneron......…

Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?

Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on…

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day....…

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

$250,000 top award goes to Neel Moudgal in the nations oldest and most prestigious science and math competition for high…

Regeneron Pharmaceuticals: Neues Kursziel

Toronto (www.aktiencheck.de) - Rating-Update: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, belässt die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075,…

Regeneron Borrows From Big Pharma Playbook

Eylea, the companys top-selling blockbuster, isnt going away soon....…

Regeneron (REGN) Stock Moves -0.19%: What You Should Know

Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session....…

2 Biotech Stocks You Can Buy and Hold for the Next Decade

Regeneron and Sarepta Therapeutics have been on fire so far this year....…

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

Sanofis (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA...…

Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron: CHMP Backs Libtayo/Chemotherapy Combo in Advanced Non-Small Cell Lung Cancer

Regeneron: CHMP Backs Libtayo/Chemotherapy Combo in Advanced Non-Small Cell Lung Cancer...…

Regeneron Pharmaceuticals: Neues Kursziel

San Francisco (www.aktiencheck.de) - Rating-Update: Mohit Bansal, Analyst von Wells Fargo Advisors, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075,…

MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approval

First-to-market Regeneron/Sanofis Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings…

Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN

Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN...…

9 Healthcare Stocks That Fewer Bears Target

Cigna, Regeneron, Centene, and six other healthcare stocks have seen short interest drop by at least 40% recently. Fewer investors…

Regeneron wins FDA nod for Eylea to prevent infant blindness

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 2.890.400$

Goldstein, Joseph L. - Aufsichtsrat - Tag der Transaktion: 2023-02-06...…

Insiderhandel: EVP Finance CFO verkauft Aktien von Regeneron Pharmaceuticals im Wert von 564.966$

Landry, Robert E. - Vorstand - Tag der Transaktion: 2023-02-03...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 795.359$

Bassler, Bonnie L. - Aufsichtsrat - Tag der Transaktion: 2023-02-03...…

Insiderhandel: EVP Finance CFO verkauft Aktien von Regeneron Pharmaceuticals im Wert von 593.238$

Landry, Robert E. - Vorstand - Tag der Transaktion: 2023-02-06...…

Thinking about trading options or stock in Catalent, Tesla, IDEXX Laboratories, Exxon Mobil, or Regeneron Pharmaceuticals?

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTLT, TSLA, IDXX, XOM, and REGN. Click…

Form 10-K REGENERON PHARMACEUTICAL For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 75.615$

Ryan, Arthur F. - Aufsichtsrat - Tag der Transaktion: 2023-02-01...…

Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 827.409$

Mccourt, Marion - Vorstand - Tag der Transaktion: 2023-02-01...…

Dow & Co im Minus, Tech-Werte deutlich unter Druck: American Express, Apple, Regeneron und Tesla dennoch stark, Amazon, Home Depot und Microsoft schwach – der Tag an der Wall Street

Gewinnmitnahmen haben zum Wochenschluss die jüngste Rally der US-Technologiewerte ausgebremst. Für Ernüchterung sorgten enttäuschende Quartalsberichte zweier Schwergewichte der Tech-Branche. Hinzu…

dpa-AFX ProFeed